Literature DB >> 15620891

Characterization and quantification of C-polysaccharide in Streptococcus pneumoniae capsular polysaccharide preparations.

Qiuwei Xu1, Chitrananda Abeygunawardana, Assunta S Ng, Annie W Sturgess, Bryan J Harmon, John P Hennessey.   

Abstract

Purified capsular polysaccharide preparations from Streptococcus pneumoniae that are used for vaccine production typically contain residual levels of C-polysaccharide (C-Ps). Residual C-Ps is typically found in one of two forms, either chemically linked to the capsular polysaccharide (bound) or present by itself (free). Two analytical methods have been developed and applied to determine the relative percentages of the two C-Ps forms present in various capsular polysaccharide preparations. Both methods differentiate the two forms of C-Ps according to the difference of their hydrodynamic sizes. One method is based on labeling C-Ps with a fluorescent tag and separating the two forms of C-Ps by high-performance size exclusion chromatography with on-line refractive index and fluorescence detection, and the other method is based on measuring self-diffusion rates of the two forms of C-Ps by nuclear magnetic resonance (NMR) and quantifying each form with deconvolution. Both methods were evaluated for relative accuracy, precision, and ease of application, and they were found to provide comparable results for a large number of pneumococcal polysaccharide preparations. These analyses, combined with other quantitative NMR measurement of total C-Ps in the polysaccharide powder, provide a more refined means of evaluating the amount of each form of C-Ps in polysaccharide preparations targeted for vaccine production.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15620891     DOI: 10.1016/j.ab.2004.10.019

Source DB:  PubMed          Journal:  Anal Biochem        ISSN: 0003-2697            Impact factor:   3.365


  8 in total

1.  Structure and molecular characterization of Streptococcus pneumoniae capsular polysaccharide 10F by carbohydrate engineering in Streptococcus oralis.

Authors:  Jinghua Yang; Nirav Y Shelat; C Allen Bush; John O Cisar
Journal:  J Biol Chem       Date:  2010-05-27       Impact factor: 5.157

2.  Evaluation of pneumococcal polysaccharide immunoassays using a 22F adsorption step with serum samples from infants vaccinated with conjugate vaccines.

Authors:  Jan T Poolman; Carl E Frasch; Helena Käyhty; Pascal Lestrate; Shabir A Madhi; Isabelle Henckaerts
Journal:  Clin Vaccine Immunol       Date:  2009-11-04

3.  The use of 1H-31P GHMBC and covariance NMR to unambiguously determine phosphate ester linkages in complex polysaccharide mixtures.

Authors:  Edward R Zartler; Gary E Martin
Journal:  J Biomol NMR       Date:  2011-09-16       Impact factor: 2.835

4.  Identification of 3-O-acetylglycerol, a novel structural element in bacterial polysaccharides.

Authors:  Edward R Zartler; Richard J Porambo; Carrie L Anderson; Jigui Yu; Moon H Nahm
Journal:  Carbohydr Res       Date:  2009-09-22       Impact factor: 2.104

5.  Structure of the capsular polysaccharide of pneumococcal serotype 11A reveals a novel acetylglycerol that is the structural basis for 11A subtypes.

Authors:  Edward R Zartler; Richard J Porambo; Carrie L Anderson; Lorenzo H Chen; Jigui Yu; Moon H Nahm
Journal:  J Biol Chem       Date:  2008-12-29       Impact factor: 5.157

6.  Fully human monoclonal antibodies from antibody secreting cells after vaccination with Pneumovax®23 are serotype specific and facilitate opsonophagocytosis.

Authors:  Kenneth Smith; Jennifer J Muther; Angie L Duke; Emily McKee; Nai-Ying Zheng; Patrick C Wilson; Judith A James
Journal:  Immunobiology       Date:  2012-09-03       Impact factor: 3.144

7.  The human natural anti-αGal antibody targets common pathogens by broad-spectrum polyreactivity.

Authors:  Jens Magnus Bernth Jensen; Sune Skeldal; Mikkel Steen Petersen; Bjarne Kuno Møller; Steen Hoffmann; Jens Christian Jensenius; Uffe B Skov Sørensen; Steffen Thiel
Journal:  Immunology       Date:  2021-01-04       Impact factor: 7.397

8.  Rare, high-affinity anti-pathogen antibodies from human repertoires, discovered using microfluidics and molecular genomics.

Authors:  Adam S Adler; Rena A Mizrahi; Matthew J Spindler; Matthew S Adams; Michael A Asensio; Robert C Edgar; Jackson Leong; Renee Leong; Lucy Roalfe; Rebecca White; David Goldblatt; David S Johnson
Journal:  MAbs       Date:  2017-08-28       Impact factor: 5.857

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.